Uwe Platzbecker

Research interests

Publications

• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

  Leukemia · 2022 · https://doi.org/10.1038/s41375-022-01613-1

• Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

  NEJM Evidence · 2022 · https://doi.org/10.1056/evidoa2200008

• Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.01659

• Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

  Leukemia · 2021 · https://doi.org/10.1038/s41375-021-01328-9

• Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

  The Lancet Haematology · 2020 · https://doi.org/10.1016/s2352-3026(19)30236-4

• Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

  Nature Medicine · 2020 · https://doi.org/10.1038/s41591-020-1008-z

• Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

  The Lancet Haematology · 2020 · https://doi.org/10.1016/s2352-3026(20)30205-2

• Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1908892

• Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

  Bone Marrow Transplantation · 2020 · https://doi.org/10.1038/s41409-020-0803-y

• Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

  Blood · 2019 · https://doi.org/10.1182/blood-2019-01-894980

• Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30580-1

• The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

  Blood Advances · 2018 · https://doi.org/10.1182/bloodadvances.2018019414

• Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

  The Lancet Haematology · 2017 · https://doi.org/10.1016/s2352-3026(17)30237-5

• Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2016.70.7349

• Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel

  Blood · 2017 · https://doi.org/10.1182/blood-2016-06-724500

• Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2016.67.1982

• Myelodysplastic Cells in Patients Reprogram Mesenchymal Stromal Cells to Establish a Transplantable Stem Cell Niche Disease Unit

  Cell stem cell · 2014 · https://doi.org/10.1016/j.stem.2014.02.014

• Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1300874

• Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

  Blood · 2013 · https://doi.org/10.1182/blood-2013-03-492884

• A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

  Blood · 2011 · https://doi.org/10.1182/blood-2011-01-330126

• Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.30.9245

• Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

  Leukemia · 2011 · https://doi.org/10.1038/leu.2011.234

• Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

  Bone Marrow Transplantation · 2008 · https://doi.org/10.1038/bmt.2008.316

• Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

  Blood · 2002 · https://doi.org/10.1182/blood.v99.12.4326

Current projects

No projects listed.